139 related articles for article (PubMed ID: 38537697)
21. Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion.
van Gent M; Gram AM; Boer IGJ; Geerdink RJ; Lindenbergh MFS; Lebbink RJ; Wiertz EJ; Ressing ME
J Gen Virol; 2015 Apr; 96(Pt 4):858-865. PubMed ID: 25502648
[TBL] [Abstract][Full Text] [Related]
22. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
23. Role of Viral and Host microRNAs in Immune Regulation of Epstein-Barr Virus-Associated Diseases.
Iizasa H; Kim H; Kartika AV; Kanehiro Y; Yoshiyama H
Front Immunol; 2020; 11():367. PubMed ID: 32194570
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.
van Gent M; Braem SG; de Jong A; Delagic N; Peeters JG; Boer IG; Moynagh PN; Kremmer E; Wiertz EJ; Ovaa H; Griffin BD; Ressing ME
PLoS Pathog; 2014 Feb; 10(2):e1003960. PubMed ID: 24586164
[TBL] [Abstract][Full Text] [Related]
27. ebv-circRPMS1 promotes the progression of EBV-associated gastric carcinoma via Sam68-dependent activation of METTL3.
Zhang JY; Du Y; Gong LP; Shao YT; Pan LJ; Feng ZY; Pan YH; Huang JT; Wen JY; Sun LP; Chen GF; Chen JN; Shao CK
Cancer Lett; 2022 Jun; 535():215646. PubMed ID: 35304258
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
J Virol; 2018 May; 92(9):. PubMed ID: 29467311
[TBL] [Abstract][Full Text] [Related]
29. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
30. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
[TBL] [Abstract][Full Text] [Related]
31. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
32. Understanding TLR9 action in Epstein-Barr virus infection.
Zauner L; Nadal D
Front Biosci (Landmark Ed); 2012 Jan; 17(4):1219-31. PubMed ID: 22201799
[TBL] [Abstract][Full Text] [Related]
33. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth.
Tobollik S; Meyer L; Buettner M; Klemmer S; Kempkes B; Kremmer E; Niedobitek G; Jungnickel B
Blood; 2006 Dec; 108(12):3859-64. PubMed ID: 16882707
[TBL] [Abstract][Full Text] [Related]
35. EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.
Lang F; Singh RK; Pei Y; Zhang S; Sun K; Robertson ES
PLoS Pathog; 2019 Jun; 15(6):e1007796. PubMed ID: 31226160
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
37. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus nuclear antigen 3C interact with p73: Interplay between a viral oncoprotein and cellular tumor suppressor.
Sahu SK; Mohanty S; Kumar A; Kundu CN; Verma SC; Choudhuri T
Virology; 2014 Jan; 448():333-43. PubMed ID: 24314664
[TBL] [Abstract][Full Text] [Related]
39. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival.
Wang LW; Wang Z; Ersing I; Nobre L; Guo R; Jiang S; Trudeau S; Zhao B; Weekes MP; Gewurz BE
PLoS Pathog; 2019 Sep; 15(9):e1008030. PubMed ID: 31518366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
